Differences in innate immune signaling between alcoholic and non-alcoholic steatohepatitis

被引:29
|
作者
Petrasek, Jan [1 ]
Csak, Timea [1 ]
Ganz, Michal [1 ]
Szabo, Gyongyi [1 ]
机构
[1] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA
关键词
alcoholic liver disease; alcoholic steatohepatitis; inflammasome; innate immunity; interleukin-1; beta; interleukin-1 receptor antagonist; Kupffer cells; non-alcoholic steatohepatitis; Toll-like receptors; INDUCED LIVER-INJURY; IL-1 RECEPTOR ANTAGONIST; NECROSIS-FACTOR-ALPHA; TOLL-LIKE RECEPTOR-4; DIET-INDUCED OBESITY; RAT KUPFFER CELLS; FATTY LIVER; INTESTINAL PERMEABILITY; HEPATIC STEATOSIS; PLASMA ENDOTOXIN;
D O I
10.1111/jgh.12020
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The similar histopathological characteristics of alcoholic steatohepatitis (ASH) and nonalcoholic steatohepatitis (NASH), and the crucial role of the innate immune response in both conditions may lead to the assumption that ASH and NASH represent the same pathophysiological entities caused by different risk factors. In this review paper, we elaborate on the pathophysiological differences between these two entities and highlight the disease-specific involvement of signaling molecules downstream of the Toll-like receptor 4, and the differential mechanism by which the inflammasome contributes to ASH versus NASH. Our findings emphasize that ASH and NASH have disease-specific mechanisms and therefore represent distinct biological entities. Further studies are needed to dissect the emerging differences in pathogenesis of these two conditions.
引用
收藏
页码:93 / 98
页数:6
相关论文
共 50 条
  • [21] Emerging drugs for non-alcoholic steatohepatitis
    Tomeno, Wataru
    Yoneda, Masato
    Imajo, Kento
    Ogawa, Yuji
    Kessoku, Takaomi
    Saito, Satoru
    Eguchi, Yuichiro
    Nakajima, Atsushi
    EXPERT OPINION ON EMERGING DRUGS, 2013, 18 (03) : 279 - 290
  • [22] Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science
    Gurmehr Brar
    Hidekazu Tsukamoto
    Journal of Gastroenterology, 2019, 54 : 218 - 225
  • [23] Natural products that target macrophages in treating non-alcoholic steatohepatitis
    Li, Chun-Lin
    Zhou, Wen-Jun
    Ji, Guang
    Zhang, Li
    WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26 (18) : 2155 - 2165
  • [24] Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis
    Bonkovsky, HL
    Jawaid, Q
    Tortorelli, K
    LeClair, P
    Cobb, J
    Lambrecht, RW
    Banner, BF
    JOURNAL OF HEPATOLOGY, 1999, 31 (03) : 421 - 429
  • [25] Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma
    Ocker, Matthias
    WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26 (03) : 279 - 290
  • [26] Alcoholic and non-alcoholic steatohepatitis: Who is affected and what can we do for them?
    Gallego-Duran, Rocio
    Ampuero, Javier
    Funuyet, Jorge
    Romero-Gomez, Manuel
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2013, 36 (09): : 587 - 596
  • [27] Non-alcoholic steatohepatitis: a microbiota-driven disease
    Moschen, Alexander R.
    Kaser, Susanne
    Tilg, Herbert
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2013, 24 (11) : 537 - 545
  • [28] The Role of Interferon Regulatory Factors in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Zhang, Chunye
    Liu, Shuai
    Yang, Ming
    GASTROENTEROLOGY INSIGHTS, 2022, 13 (02) : 148 - 161
  • [29] CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Sila Cocciolillo
    Giustino Parruti
    Leonardo Marzio
    World Journal of Hepatology, 2014, (07) : 496 - 503
  • [30] Sex difference in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Tomiya, Tomoaki
    HEPATOLOGY RESEARCH, 2010, 40 (01) : 108 - 110